Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The group could soon provide clarity on CTX112’s regulatory path.
Boehringer discontinues brigimadlin while others continue to struggle.
The THIO-104 study listing is live, along with questions about funding the trial.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
